Abstract
The history of antitumor drug discovery has essentially been the use of two lymphocytic leukemias of mice as selection funnels through which all agents needed to pass in order to advance toward clinical development (L1210 prior to 1975 and P388 after 1975). It is thus not surprising that agents in the clinic are highly active against these tumor systems. However, none of the agents discovered by these leukemias are tumor specific (i.e., active against all tumors), and none of the agents are broadly active against solid tumors of either rodents or humans (1–3). An example contrasting the responsiveness of transplantable solid tumors of mice and the two leukemias is shown in Table-1. The lack of responsiveness of these solid tumors of mice is not unlike those seen in human lung, pancreatic, colon, and prostate tumors. The point to emphasize is that the lack of solid tumor activity of available antitumor agents is not species related. The fault does not lie with the omission of human tumors in the initial selection process, but rather with the omission of solid tumors.
Eastman Kodak Co./Sterling Drug Inc.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Corbett TH, Valeriote FA and Baker LH: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest. New Drugs 5:3–20, 1987.
Corbett TH, Roberts BJ, Leopold WR et al: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 44:717–726, 1984.
Skipper H: Drug evaluation in experimental tumor systems: Potential and limitations in 1961. Cancer Chemother Rep. 16:11–19, 1962.
Corbett TH: A selective soft agar assay for drug discovery. Proc. Am. Assoc. for Cancer Res. 25:325, 1984.
Corbett TH: A selective soft agar assay for drug discovery. Proc. Am. Assoc. for Cancer Res. 26:332, 1985.
Corbett TH, Wozniak A, Gerpheide S and Hanka L: A selective two-tumor soft agar assay for drug discovery. In: In Vitro and In Vivo Models for Detection of New Antitumor Drugs: Proceedings 14th International Congress of Chemotherapy. LJ Hanka, T Kondo, and RJ White (eds) Univ. of Tokyo Press, pp. 5–14, 1986.
Corbett TH, Bissery M, Wozniak A et al: Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest. New Drugs 4:207–220, 1986.
Corbett TH and Valeriote F: Rodent models in experimental chemotherapy. In: The Use of Rodent Tumors in Experimental Cancer Therapy. RF Kallman (ed), Pergamon Press, pp. 233–247, 1987.
LoRusso PM, Polin L, Bissery MC et al: Activity of batracylin (NSC-320846) against solid tumors of mice. Invest. New Drugs 6:295–306, 1989.
LoRusso PM, Polin L, Biernat LA et al: Activity of detailiptinium (NSC 311152) against solid tumors of mice. Invest. New Drugs 8:253–261, 1990.
LoRusso PM, Wozniak AJ, Polin L et al: Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res. 50:4900–4905, 1990.
Corbett TH, Leopold WR, Dykes DJ et al: Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res. 42:1707–1715, 1982.
Pazdur R, Redman BG, Corbett T et al: Phase I trial of spirohydantoin mustard (spiromustine/NSC 172112) and evaluation of toxicity and schedule in a murine model. Cancer Res. 47:4213–4217, 1987.
Corbett TH, Bissery MC, LoRusso PM, Polin L: 5-Fluorouracil containing combinations in murine tumor systems. Invest. New Drugs 7:37–49, 1989.
Corbett TH, Griswold DP Jr, Roberts BJ et al: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(5):2660–2680, 1977.
Corbett TH, Roberts BJ, Trader MW et al: Response of transplantable tumors of mice of anthracenedione derivatives alone and in combination with clincally useful agents. Cancer Treat. Rep. 6:1187–1200, 1982.
LoRusso PM, Polin L, Aukerman SL et al: Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. Cancer Res. 50:5876–5882, 1990.
Corbett TH, Griswold DP, Roberts BJ et al: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat. Rep. 62(10): 1471–1488, 1978.
Griswold DP Jr, Corbett TH, Schabel FM Jr: Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure. Cancer Treat. Rep. 65(2):51–54, 1981.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Corbett, T.H. et al. (1992). Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay. In: Valeriote, F.A., Corbett, T.H., Baker, L.H. (eds) Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Developments in Oncology, vol 68. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3492-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3492-1_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6548-8
Online ISBN: 978-1-4615-3492-1
eBook Packages: Springer Book Archive